LONDON--Pharmaceutical company GlaxoSmithKline PLC (GSK.LN) said
Tuesday that the U.S. Food and Drug Administration has approved its
Tanzeum, or albiglutide, drug for type 2 diabetes treatment.
MAIN FACTS:
-FDA has approved Tanzeum for injection, for subcutaneous use,
as a once-weekly treatment for type 2 diabetes.
-Tanzeum has been approved as an adjunct to diet and exercise to
improve glycemic control in adults with type 2 diabetes
mellitus.
-Approval is based on the results of the company's Phase III
Harmony program.
-Anticipates the U.S. launch of Tanzeum in the third quarter of
2014.
-Albiglutide was licensed by the European Medicines Agency in
March 2014, under the brand name Eperzan, for use in adult patients
with type 2 diabetes.
-Shares on Tuesday closed at 1547 pence, valuing the company at
GBP75.17 billion.
-Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires